Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cordarone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Cordarone | DRUG | - |
Inclusion Criteria: * Be a healthy male or female 18 to 59 years of age, inclusive. Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial and must have a negative serum pregnancy test at screening and upon check-in to the study faci...
Cordarone is a small molecule drug developed by Baxter International Inc. (ticker: BAX). It is in Phase 1 clinical development. The specific medical conditions it is intended to treat have not been disclosed. One Phase 1 trial of Cordarone has been completed.
Cordarone is being developed by Baxter International Inc., which trades under the ticker symbol BAX. Baxter is the sponsor associated with the clinical development program for Cordarone.
Cordarone is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. Because the available information does not indicate regulatory approval, Cordarone should be considered investigational.
Cordarone has been studied in one completed Phase 1 trial, NCT00420953, titled Relative Bioavailability of PM101 IV and Cordarone IV. The trial enrolled healthy volunteers age 18 and older of all sexes and was conducted in Canada. It used a randomized, double-blind design with an uncontrolled control type.